Pro Medicus Can Beat Profit Hopes But Valuation Full -- Market Talk

Dow Jones

Jan 15, 2025

2154 GMT - Jefferies raises its price target on imaging-tech provider Pro Medicus by 79% to A$250.00/share, but concludes that only a hold call is warranted on its stock. That's because Pro Medicus ended Tuesday at A$254.00, more than double year-ago levels. "Valuations are stretched to a point beyond our justification, yet we see upside risk to consensus estimates," analyst Wei Sim says. Jefferies raises its earnings forecasts for FY 2026-2027 by 37-71%, anticipating more health care companies will move away from legacy tech providers over the next 3-5 years. Its revised FY 2026-2027 earnings projections are 13%-32% ahead of consensus hopes. Still, Jefferies says Pro Medicus "needs to penetrate 98% of U.S. market to justify its current valuation." (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

January 14, 2025 16:54 ET (21:54 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503820036"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503820036\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503820036?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-15 05:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503820036","market":"other","top_or_hot":-1,"title":"Pro Medicus Can Beat Profit Hopes But Valuation Full -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2154 GMT - Jefferies raises its price target on imaging-tech provider Pro Medicus by 79% to A$250.00/share, but concludes that only a hold call is warranted on its stock. That's because Pro Medicus ended Tuesday at A$254.00, more than double year-ago levels. \"Valuations are stretched to a point beyond our justification, yet we see upside risk to consensus estimates,\" analyst Wei Sim says. Jefferies raises its earnings forecasts for FY 2026-2027 by 37-71%, anticipating more health care companies will move away from legacy tech providers over the next 3-5 years. Its revised FY 2026-2027 earnings projections are 13%-32% ahead of consensus hopes. Still, Jefferies says Pro Medicus \"needs to penetrate 98% of U.S. market to justify its current valuation.\" (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2025 16:54 ET (21:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pro Medicus Can Beat Profit Hopes But Valuation Full -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPro Medicus Can Beat Profit Hopes But Valuation Full -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-15 05:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2154 GMT - Jefferies raises its price target on imaging-tech provider Pro Medicus by 79% to A$250.00/share, but concludes that only a hold call is warranted on its stock. That's because Pro Medicus ended Tuesday at A$254.00, more than double year-ago levels. \"Valuations are stretched to a point beyond our justification, yet we see upside risk to consensus estimates,\" analyst Wei Sim says. Jefferies raises its earnings forecasts for FY 2026-2027 by 37-71%, anticipating more health care companies will move away from legacy tech providers over the next 3-5 years. Its revised FY 2026-2027 earnings projections are 13%-32% ahead of consensus hopes. Still, Jefferies says Pro Medicus \"needs to penetrate 98% of U.S. market to justify its current valuation.\" (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2025 16:54 ET (21:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PME.AU","symbol_name":"PRO MEDICUS LTD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2503820036","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503820036","pubTimestamp":1736891640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2154 GMT - Jefferies raises its price target on imaging-tech provider Pro Medicus by 79% to A$250.00/share, but concludes that only a hold call is warranted on its stock. That's because Pro Medicus ended Tuesday at A$254.00, more than double year-ago levels. \"Valuations are stretched to a point beyond our justification, yet we see upside risk to consensus estimates,\" analyst Wei Sim says. Jefferies raises its earnings forecasts for FY 2026-2027 by 37-71%, anticipating more health care companies will move away from legacy tech providers over the next 3-5 years. Its revised FY 2026-2027 earnings projections are 13%-32% ahead of consensus hopes. Still, Jefferies says Pro Medicus \"needs to penetrate 98% of U.S. market to justify its current valuation.\" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PME.AU":"PRO MEDICUS LTD","BK7094":"医疗保健技术"},"translate_title":"Pro Medicus可以超出利润预期，但估值已满——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PME.AU":0.9},"content_text":"2154 GMT - Jefferies raises its price target on imaging-tech provider Pro Medicus by 79% to A$250.00/share, but concludes that only a hold call is warranted on its stock. That's because Pro Medicus ended Tuesday at A$254.00, more than double year-ago levels. \"Valuations are stretched to a point beyond our justification, yet we see upside risk to consensus estimates,\" analyst Wei Sim says. Jefferies raises its earnings forecasts for FY 2026-2027 by 37-71%, anticipating more health care companies will move away from legacy tech providers over the next 3-5 years. Its revised FY 2026-2027 earnings projections are 13%-32% ahead of consensus hopes. Still, Jefferies says Pro Medicus \"needs to penetrate 98% of U.S. market to justify its current valuation.\" (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2025 16:54 ET (21:54 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}